Study on the TIL and NK of IL-2 injected via pelvic retroperitoneal space in gynecological cancer patient

Journal of Sichuan University (Medical Science)

Volumn 35, Issue 3, 2004, Pages 406-408

  Chen, Jie ^a   Cao, Ze Yi ^a   Zhang, Ping ^a   Peng, Zhi Lan ^a   Yang, Yan Lin ^a   Bi, Jian Hong ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Biotherapy IL 2; Gynecological cancer; Pelvic retroperitoneal space; TIL

Indexed keywords

BIOLOGICAL RESPONSE MODIFIER; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; FLUOROURACIL; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR;

ARTICLE; CANCER PATIENT; CELL COUNT; CONTROLLED STUDY; DRUG EFFECT; FEASIBILITY STUDY; FEMALE; GYNECOLOGIC CANCER; HUMAN; HUMAN CELL; NATURAL KILLER CELL; PELVIS LYMPH NODE; RETROPERITONEUM; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TUMOR ASSOCIATED LEUKOCYTE;

EID: 2542457695     PISSN: 1672173X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Oldham RK. Biologicals and biological response modifiers: fourth modality of cancer treatment. Cancer Treat Rep, 1984; 68(1):221.
2. Den Otter W, Maas RA, Koten JW, et al. Effective immunotherapy with local low doses of interleukin-2. In Vivo, 1991;5(6):561.
3. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science, 1986;233(4770):1318.
4. Schofield L, McConville MJ, Hansen D, et al. CD1d-restricted immunoglobulin G formation to GPI-anchored antigens mediated by NKT cells. Science, 1999;283(5399): 225.
5. Lanier LL. Follow the leader: NK cell receptors for classical and nonclassical MHC class I. Cell,1998;92(6):705.
6. Farace F, Angevin E, Dietrich PY, et al. Low-dose IL-2 treatment: activation of discrete T-and NK-cell sub-populations in vivo. Int J Cancer, 1995;62(5):523.
7. Cao Zeyi, Zhang dan, Pen Zilan, et al. Chemotherapy for lymphatic metastatic gynecologic cancer via pelvic retroperitoneal cannulation. Gynecol Oncol, 1996;63(9):358.